Finanzen von CalciMedica Inc (CALC)CALCCalciMedica Inc

Evaluating the bottom line, CalciMedica Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -365.70%, provide a clear picture of how effectively CALC converts its operational activities into shareholder value.

In the context of the broader market, CALC competes directly with industry leaders such as PHIO and RGNT. With a market capitalization of $9.29M, it holds a significant position in the sector. When comparing efficiency, CALC's gross margin of N/A stands against PHIO's N/A and RGNT's N/A. Such benchmarking helps identify whether CalciMedica Inc is trading at a premium or discount relative to its financial performance.

CalciMedica has faced significant losses with a net income of -7.65 million in Q2 2026, and an EPS of -0.45, indicating ongoing financial struggles. However, the company reported a substantial increase in other income, rising to $10.6 million in Q1 2026 from $1.5 million in Q1 2025, showing potential for recovery.